Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

In a report released today, James Rose from Barclays maintained a Buy rating on Experian (EXPGF – Research Report), with a price target of ...

Barclays shares have carried on where they left off in 2024, by climbing far faster than the FTSE 100. Harvey Jones wonders ...

This article looks at the FTSE 100 index and what to expect next week as several blue chip companies like Barclays and ...